Related Experiment Video
Updated: Apr 11, 2026
Oropharyngeal Administration of Bleomycin in the Murine Model of Pulmonary Fibrosis
Published on: May 9, 2025
The code of non-coding RNAs in lung fibrosis
Huachun Cui1, Na Xie, Victor J Thannickal
1Division of Pulmonary, Allergy, and Critical Care Medicine, Department of Medicine, University of Alabama at Birmingham, 901 19th St. So., BMR II 233, Birmingham, AL, 35294, USA.
Abstract:
The pathogenesis of pulmonary fibrosis is a complicated and complex process that involves phenotypic abnormalities of a variety of cell types and dysregulations of multiple signaling pathways. There are numerous genetic, epigenetic and post-transcriptional mechanisms that have been identified to participate in the pathogenesis of this disease. However, efficacious therapeutics developed from these studies have been disappointingly limited. In the past several years, a group of new molecules, i.e., non-coding RNAs (ncRNAs), has been increasingly appreciated to have critical roles in the pathological progression of lung fibrosis. In this review, we summarize the recent findings on the roles of ncRNAs in the pathogenesis of this disorder. We analyze the translational potential of this group of molecules in treating lung fibrosis. We also discuss challenges and future opportunities of studying and utilizing ncRNAs in lung fibrosis.
Insights
Non-coding RNAs (ncRNAs) play a crucial role in the complex pathogenesis of pulmonary fibrosis. Understanding these molecules offers new therapeutic potential for treating this debilitating lung disease.
Area of Science:
- Pulmonary medicine
- Molecular biology
- Genetics
Background:
- Pulmonary fibrosis pathogenesis involves complex cellular and signaling pathway dysregulation.
- Genetic, epigenetic, and post-transcriptional mechanisms contribute to lung fibrosis.
- Current therapeutics for pulmonary fibrosis remain limited.
Purpose of the Study:
- To review recent findings on the role of non-coding RNAs (ncRNAs) in pulmonary fibrosis pathogenesis.
- To analyze the translational potential of ncRNAs as therapeutics for lung fibrosis.
- To discuss challenges and future directions in ncRNA research for lung fibrosis.
Main Methods:
- Literature review of recent studies on ncRNAs and pulmonary fibrosis.
- Analysis of ncRNA functions in lung fibrosis models and patient data.
- Evaluation of ncRNA-based therapeutic strategies.
Main Results:
- Non-coding RNAs (ncRNAs) are increasingly recognized for their critical roles in the pathological progression of lung fibrosis.
- Specific ncRNAs have been identified as key regulators of fibrotic processes.
- ncRNAs demonstrate significant potential for targeted therapeutic interventions.
Conclusions:
- ncRNAs represent a promising class of molecules for developing novel treatments for pulmonary fibrosis.
- Further research is needed to overcome challenges in studying and utilizing ncRNAs in clinical settings.
- Exploiting ncRNAs offers new opportunities for managing and potentially reversing lung fibrosis.
Related Concept Videos
02:39lncRNA - Long Non-coding RNAs
02:39lncRNA - Long Non-coding RNAs
01:13Formation of Muscle Fibers from Myoblasts
Muscle progenitor cells (MPCs) are formed from the myotomes. MPCs express genes that encode the transcription factors Pax3 and Pax7. Along with Pax 3/7, other transcription...